TY - JOUR T1 - 64Cu- DOTA,1-Nal(3)]-octreotide (DOTANOC) PET/CT in Neuroendocrine Tumors: Initial Experience in Single Centre in Mexico. JF - Journal of Nuclear Medicine JO - J Nucl Med SP - 129 LP - 129 VL - 61 IS - supplement 1 AU - Francisco Garcia-Perez AU - Hector Valdovinos AU - Paulina Munguia AU - Irma Soldevilla-Gallardo AU - Sevastian Medina-Ornelas AU - Roberto Pedrero-Piedras AU - Filiberto Lemus AU - Joel Vargas-Ahumada Y1 - 2020/05/01 UR - http://jnm.snmjournals.org/content/61/supplement_1/129.abstract N2 - 129Introduction: The use of molecular imaging using radiolabeled somatostatin analogs has revolutionized the management of Neuroendocrine tumors (NETs). Recently 64 Copper (64Cu) has been used as an alternative to 68 Gallium (68Ga) in peptide labeling, 64Cu has certain advantages such as long half-life and a decay profile that can be used for positron emission tomography imaging and radionuclide therapy. (T1 / 2 = 12.7 hours; β +: 19%, β−: 38%). Materials and Methods: From March 2019 to December 2019; seventeen patients (10 men and 7 woman, aged 42 to 69 (mean age 65.5 +/- 10.1 years) with histopathological and immunohistochemical diagnosis of neuroendocrine tumor (12 well differentiated and 5 moderately differentiated) were scanned for staging (n=15) and re staging (n=2). All patients underwent whole-body PET / CT scans 60 - 70 min after the intravenous injection of 185 - 259 Mbq of 64Cu-DOTA,1-Nal(3)]-octreotide (64Cu-DOTANOC). PET / CT images were analyzed semi-quantitatively using SUVmax. 64Cu was produced in a IBA twin 18 MeV Cyclotron with the irradiation of natNi in a Nirta solid target and DOTANOC was radiolabeled by incubation in acid medium and purified in solid phase reaching a yield higher than 95%. Results: 64Cu-DOTANOC was well tolerated in all patients and none adverse effects were noticed. 64Cu-DOTANOC was positive in 16 of 18 patients and found 57 lesions (21 in liver, 18 bone lesions, 12 in lymph nodes, 3 lung, 3 peritoneal nodules). The patients with negative scan were studied for restaging after surgical intervention with curative intention. The SUVmax of tumoral lesions ranged between 8.73 to 50.42 (mean 18.5 +/- 16.24), SUVmax [mean ± SD] in normal organs of biodistribution like hypophysis, thyroid, liver, spleen, kidney, adrenal, and uncinate process were 5.68 +/- 2.3, 2.6 +/- 1.8, 10.29 +/- 5.9, 25.1 +/- 15.35, 14.6 +/-8.9, 13.9 +/- 7.4, 10.5 +/- 6.5 respectively. One week after 5 patients were scanned complementary with 68Ga-DOTATOC. 64Cu-DOTANOC found 4 lymph nodes and 1 peritoneal nodule that was not seen with 68Ga-DOTATOC, this findings did not had clinical impact. SUVmax between both radiopharmaceuticals in tumoral lesions no shows significant differences (64Cu DOTANOC 14.2 +/- 5.4 vs 68Ga-DOTATOC 13.1 +/- 3.5) p=0.51. Conclusions: 64Cu-DOTANOC is a highly effective radiopharmaceutical in the detection of neuroendocrine tumors, shows a biodistribution and sensitivity similar to 68Ga-DOTATOC, probably with greater detection capacity due to the affinity to a greater number of somatostatin receptors (SSTR2, SSTR3, SSTR5), additionally its physical characteristics give it a potential theragnostic use, and its long live could be used to acquire late images to improve accuracy or to increase the accessibility to this type of molecular imaging in centers that do not have a 68Ge/68Ga generator. ER -